Using anti-PD-(L)1 agents in early-stage cancers vs. limiting their use to the advanced/metastatic setting resulted in gains in total life-years (+1,280; a gain of 3%), recurrence-/event-/disease-free life-years (+3,416; +10%), and QALYs (+1,422; +4%). The gene discussed is CD274; the disease is cancer.